Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$109.85 USD

109.85
571,216

-0.16 (-0.15%)

Updated May 6, 2024 04:00 PM ET

After-Market: $109.84 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for JAZZ

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Jazz Pharmaceuticals PLC [JAZZ]

Reports for Purchase

Showing records 221 - 240 ( 246 total )

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 221

09/18/2012

Company Report

Pages: 5

Favorable Markman Hearing; Reiterate Buy and $63 PT

Provider: WALLACHBETH CAPITAL, LLC

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 222

09/17/2012

Daily Note

Pages: 279

Initiating Coverage

Provider: Guggenheim Securities LLC

Price: 150.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 223

06/07/2012

Daily Note

Pages: 5

Termination of Coverage

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 224

05/09/2012

Company Report

Pages: 5

Reiterate Buy and raise PT from $57 to $64; Q1 beat and raise; EUSA to add $0.75-$0.85 EPS in 2013

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 225

04/27/2012

Company Report

Pages: 6

Reiterate Buy and $57 PT; JAZZ to acquire EUSA for $650 million cash

Provider: AURIGA USA

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 226

03/21/2012

Company Report

Pages: 5

Reiterate BUY and $57 PT; Could Prialt reach $150 million in revenue by 2016?

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 227

02/28/2012

Company Report

Pages: 6

Another Consensus-beating Quarter; Reiterate BUY and Raise Price Target from $55 to $57

Provider: AURIGA USA

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 228

01/06/2012

Company Report

Pages: 5

2012 Guidance Beats Consensus; Reiterate BUY and $55 PT

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 229

11/04/2011

Company Report

Pages: 5

Inline Q3; Visible benefit of Azur acquisition expected in 2013; Reiterate BUY and $55 PT

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 230

09/29/2011

Company Report

Pages: 16

A successful orphan drug story. Initiate coverage with BUY rating and $55 PT

Provider: AURIGA USA

Price: 50.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 231

09/06/2011

Daily Note

Pages: 3

Dropping Coverage of Biotechnology Stocks

Provider: CAPSTONE INVESTMENTS

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 232

08/01/2011

Company Report

Pages: 5

Another Great Quarter, Upside Priced In; Maintain HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 233

06/16/2011

Daily Note

Pages: 3

KEY TAKEAWAY FROM CONFERENCE CALL ON IP protection of REMS program

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 234

05/04/2011

Company Report

Pages: 6

Another good performance quarter, upsides priced in, Maintain HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 235

03/08/2011

Company Report

Pages: 6

2011 guidance in line with our prior estimates, Maintain Hold Rating

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 236

11/05/2010

Company Report

Pages: 8

BEATS CONSENSUS ON BOTH REVENUEAND PROFIT

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 237

10/12/2010

Industry Report

Pages: 9

KEY TAKEAWAYS FROM DISCUSSION ON M&A TRENDS IN PHARMACEUTICALS-BIOTECH INDUSTRY.

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 238

09/28/2010

Industry Report

Pages: 5

M&A TRENDS IN BIOTECH AND SPECIALTY PHARMA

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 239

09/23/2010

Company Report

Pages: 7

DOWNGRADE FROM BUY TO HOLD

Provider: CAPSTONE INVESTMENTS

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 240

08/31/2010

Industry Report

Pages: 15

TOP TECHNICAL PICKS AMONG OUR RESEARCH UNIVERSE

Provider: CAPSTONE INVESTMENTS

Analyst: SINE B

Price: 50.00

Research Provided by a Third Party